Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Insider Sells 5,000 Shares

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) insider Helen Louise Collins sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $219,000.00. Following the completion of the sale, the insider directly owned 25,000 shares in the company, valued at $1,095,000. This represents a 16.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

• On Friday, April 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $47.67, for a total value of $238,350.00.
• On Wednesday, March 25th, Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $35.10, for a total value of $1,404,000.00.

Bitwise MARA Option Income Strategy ETF Stock Up 2.4%

Bitwise MARA Option Income Strategy ETF stock traded up $0.41 during midday trading on Monday, hitting $17.64. The company’s stock had a trading volume of 617 shares, compared to its average volume of 5,386. The stock’s 50-day moving average price is $16.49 and its 200-day moving average price is $15.80. Bitwise MARA Option Income Strategy ETF has a 12 month low of $11.99 and a 12 month high of $54.94. The company has a market capitalization of $3.35 million, a PE ratio of 352.80 and a beta of 2.88.

About Bitwise MARA Option Income Strategy ETF

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.